Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
12.73
-0.71 (-5.28%)
At close: Apr 7, 2026, 4:00 PM EDT
12.78
+0.04 (0.35%)
After-hours: Apr 7, 2026, 4:17 PM EDT
Contineum Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Contineum Therapeutics stock have a consensus rating of "Buy" and an average price target of $19, which forecasts a 49.25% increase in the stock price over the next year. The lowest target is $14 and the highest is $22.
Price Target: $19 (+49.25%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2026.
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $14 → $20 | Buy | Maintains | $14 → $20 | +57.11% | Mar 6, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $23 → $14 | Buy → Hold | Downgrades | $23 → $14 | +9.98% | Jan 8, 2026 |
| Baird | Baird | Buy Maintains $16 → $14 | Buy | Maintains | $16 → $14 | +9.98% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $22 | Buy | Maintains | $25 → $22 | +72.82% | Nov 21, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $20 | Buy | Initiates | $20 | +57.11% | Sep 25, 2025 |
Financial Forecast
Revenue This Year
6.12M
Revenue Next Year
2.24M
from 6.12M
Decreased by -63.33%
EPS This Year
-2.24
from -2.17
EPS Next Year
-2.14
from -2.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 31.5M | 11.6M | |||
| Avg | 6.1M | 2.2M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 88.7% | |||
| Avg | - | -63.3% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.00 | -1.72 | |||
| Avg | -2.24 | -2.14 | |||
| Low | -2.69 | -2.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.